Infection Risk Management

Aarcher provides infection risk management support to assist leadership and facility managers adapt to ongoing outbreak conditions, institute proactive measures to prevent infection, and prepare for future pandemics.

Return to Work Plans

Return to Work Plans provide an description of actions organizations or facilities are taking to protect employees as they return to work locations. This plan, which is developed in coordination with company leadership and facility management, is presented in a format suitable to share widely with employees.

Infection Risk Assessments

Aarcher performs assessments of facilities to document the status of workplace conditions and systems affecting potential employee exposure to pathogens and to provide facility managers with clear recommendations to mitigate infection risks. Working proactively to reduce the spread of human pathogens in the workplace protects employees and prevents operational disruptions.

Resulting recommendations apply to all human contagions, including influenza (flu), coronavirus (SARS-CoV-2)(causing COVID-19), Middle East Respiratory Syndrome (MERS), H1N1 Influenze Virus (Swine Flu), and various harmful bacteria.

Our assessors identify opportunities to minimize exposure through a variety of methods, following specific recommendations of the Centers for Disease Control (CDC), Occupational Safety and Health Administration (OSHA), World Health Organization (WHO), and other medical, research, and epidemiological organizations. We adhere to generally accepted industry practices and are guided by the National Institute of Occupational Safety and Health (NIOSH) hierarchy of controls strategy.

Assessment results are kept confidential and delivered directly to management, to allow management to evaluate resulting recommendations, provide feedback to the assessment team, and implement or phase-in accepted recommendations as appropriate.

Pandemic Response and Preparedness Plans

Aarcher prepares plans to guide both the immediate and long-term measures to protect employees and ensure business continuity. Our team works closely with corporate and facility management to understand your condition and business realities, then works with you to develop a plan establishing practical and creative strategies.

 

We are currently scheduling facility assessments and infection control strategy development support anywhere in the United States. To discuss your organizational needs, Contact Us.

Aarcher performs third-party workplace assessments to evaluate infection risks following current recommendations from the Centers for Disease Control (CDC) and other organizations and applying industry best practices. Assessments are performed by Certified Industrial Hygienists (CIH) and similarly qualified professionals, under the direction of our Science Director, Infection Prevention.

Assessors review facility policies and practices, conduct detailed facility inspections, and observe employee work practices to understand exposure pathways and identify opportunities for improvement.

Evaluated facilities receive a report documenting existing best practices and describing recommended modifications to policies, procedures, work flow modifications, and facility modifications. The confidential report is delivered directly to facility management.

To provide a complete strategy for managing infection risk over time, Aarcher provides infection prevention plans customized to the challenges faced by each facility.

  • 23 years corporate experience evaluating more than 2,000 industrial, commercial, and government facilities
  • Assessments performed by senior credentialed professionals with expertise and training in exposure assessment and control
  • Assessment results documented by a reputable and impartial third-party

Our infection risk mitigation strategies and assessment approach are directed by a senior epidemiologist and infection control expert.

Sarah Connolly, PhD, MPH brings nearly a decade of experience in infectious disease research and infection prevention to her role as Scientific Director, Infection Prevention at Aarcher, Inc. As a former public health associate with the Centers for Disease Control and Prevention, Sarah responded to infectious disease outbreaks and provided infection control guidance in a variety of settings. She regularly conducted contact-tracing and risk-assessment counseling to prevent the spread of diseases. She also has experience comparing local surveillance systems for influenza virus and writing state investigation protocols for infectious diseases.

In 2018, Sarah was a member of the 1st-place-winning team at the International Global Health Case Competition for her team’s strategy to control a fictional outbreak of a novel coronavirus at the 2022 World Cup. Their award-winning approach included methods to detect, contain, and prevent novel coronavirus cases and scalable recommendations for various levels of government and the broader community.

In addition to her breadth of public health experience, Sarah has conducted basic scientific research on the virologic and immunologic characteristics of HIV transmission as well as studied the toxic effects of nanoparticles on human lung cells. Bridging her research to public health, she has worked to develop assays for the rapid detection of measles virus and created diagnostic checklists to reduce the cost of STI testing in Zambia.

Sarah received her bachelor’s degree in Microbiology and Cell Science from the University of Florida and completed her Doctor of Philosophy in Immunology and Molecular Pathogenesis at Emory University. She also holds a Master of Public Health in Global Epidemiology from the Rollins School of Public Health at Emory University. Publications of her research can be found in prominent infectious disease journals, including the Journal of Clinical Microbiology and Virology.